Effect of pre‐transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis

Abstract

Myelofibrosis (MF) is a clonal stem cell disorder, with a median age at diagnosis of 67 years, characterized by ineffective hematopoiesis, bone marrow fibrosis, and extramedullary hematopoiesis. 1 Allogenic hematopoietic stem cell transplantation (allo-HCT) is currently the only curative treatment for patients with MF. However, allo-HCT is associated with high non-relapse mortality due to an increased risk of graft failure, secondary to the presence of splenomegaly and marrow fibrosis. [2][3][4] Deciding on the optimal CD34 cell dose is a critical